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BACKGROUND: Metastatic tumour cells are characterised by acquisition of migratory and invasive properties; properties shared by cells,
which have undergone epithelial-to-mesenchymal transition (EMT). Disabled-2 (Dab2) is a putative tumour suppressor whose
expression has been shown to be downregulated in various cancer types including breast cancer; however, its exact function in
suppressing tumour initiation or progression is unclear.
METHODS: Disabled-2 isoform expression was determined by RT–PCR analysis in human normal and breast tumour samples. Using
shRNA-mediated technology, Dab2 was stably downregulated in two cell model systems representing nontumourigenic human
mammary epithelial cells. These cells were characterised for expression of EMT markers by RT–PCR and western blot analysis.
RESULTS: Decreased expression of the p96 and p67 isoforms of Dab2 is observed in human breast tumour samples in comparison to
normal human breast tissue. Decreased Dab2 expression in normal mammary epithelial cells leads to the appearance of a constitutive
EMT phenotype. Disabled-2 downregulation leads to increased Ras/MAPK signalling, which facilitates the establishment of an
autocrine transforming growth factor b (TGFb) signalling loop, concomitant with increased expression of the TGFb2 isoform.
CONCLUSION: Loss of Dab2 expression, commonly observed in breast cancer, may facilitate TGFb-stimulated EMT, and therefore
increase the propensity for metastasis.
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Breast cancer remains the most prevalent form of cancer
diagnosed and the second-leading cause of cancer deaths in
women. The ultimate cause of death in breast cancer is generally
not because of the primary tumour itself, but rather from
metastatic spread of the tumour. Metastasis is a coordinated
process, which involves intravasation of tumour cells from the
primary site into the circulation, followed by extravasation and
establishment of a secondary tumour in a target organ (Hunter
et al, 2008). Tumour cells that possess metastatic capability have
been shown to acquire fibroblastoid invasive properties, which
allows for subsequent degradation and migration through the
extracellular matrix. These same properties are characteristic of
cells, which have undergone epithelial-to-mesenchymal transition
(EMT; Berx et al, 2007; Yang and Weinberg, 2008).
Epithelial-to-mesenchymal transition is defined as the loss of
epithelial characteristics and the acquisition of a mesenchymal
phenotype (Thiery and Sleeman, 2006). Concurrently, cells under-
going EMT alter gene expression patterns from genes required to
maintain epithelial morphology, such as E-cadherin, to expression of
mesenchymal genes, such as N-cadherin, vimentin and fibronectin.
Although cooperation between several signalling pathways occurs
during EMT, signalling by the transforming growth factor b (TGFb)
cytokine family has emerged as a key inducer of EMT in both
developmental and pathological settings (Xu et al, 2009). Transform-
ing growth factor b functions as a potent tumour suppressor in
normal epithelial cells by inhibition of cell proliferation, maintenance
of genomic stability, and stimulation of cell differentiation and
apoptosis (Massague and Gomis, 2006). An unexpected role for TGFb
as a pro-metastatic factor, however, has been shown to occur late in
tumour progression (Tang et al, 2003), which may be attributed to the
ability of TGFb to stimulate EMT. Recent studies have demonstrated
that human mammary epithelial cells, which have undergone EMT,
acquire stem cell-like characteristics, become invasive and exhibit
resistance to chemotherapy, which could also be recapitulated in
cultured cells by treatment with TGFb (Mani et al, 2008). In addition,
autocrine production of TGFb, stimulated by activation of the
Ras/Raf/MAPK pathway, has been shown to stabilise the EMT pheno-
type in vitro and in vivo (Lehmann et al, 2000; Janda et al, 2002).
Disabled-2 (Dab2) or deleted in ovarian carcinoma-2 is a
putative tumour suppressor first identified in a screen for
transcripts downregulated in ovarian tumours vs normal ovarian
surface epithelial cells (Mok et al, 1994). Disabled-2 has
subsequently been shown to be downregulated in a variety of
human tumour types including prostate (Tseng et al, 1998),
bladder (Karam et al, 2007), oesophageal (Anupam et al, 2006),
colorectal (Kleeff et al, 2002) and metastatic pancreatic cancer
(Huang et al, 2001). Comparison of genes differentially expressed
in an in vivo mouse mammary carcinogenesis model indicated that
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sDab2 was downregulated in 80% of mammary tumours (Schwahn
and Medina, 1998). In human breast tumours, loss of Dab2 protein
expression was observed in 74% of samples analyzed, whereas
expression in 10 normal breast tissue samples was maintained
(Bagadi et al, 2006). These results suggest that Dab2 may function as
a tumour suppressor in breast cancer; however, the exact role of
Dab2 in prevention of tumour initiation or progression is unclear.
Disabled-2 has been shown to have a variety of diverse roles within
the cell. Disabled-2 can facilitate endocytosis through its asso-
ciation with clathrin, the clathrin adaptor protein AP-2, and myosin
VI (Morris and Cooper, 2001; Morris et al, 2002). In addition Dab2,
through its N-terminal PTB domain, can directly bind to cell surface
receptors such as members of the LDL receptor family and various
integrin subunits (Morris and Cooper, 2001; Gallagher et al, 2004).
Last, Dab2 has been shown to modulate various signalling pathways,
including the TGFb (Hocevar et al, 2001), Wnt (Hocevar et al, 2003),
JNK (Hocevar et al, 2005), Ras/MAPK (Xu et al, 1998; Zhou and
Hsieh, 2001) and Src pathways (Zhou et al, 2003).
Cross-talk between the TGFb and Ras-MAPK signalling pathways
has been postulated to be required for both induction and
maintenance of EMT (Janda et al, 2002). As Dab2 has been shown
to modulate both pathways, we have explored whether loss of Dab2
expression in nontumourigenic human mammary epithelial cells
affects TGFb-stimulated EMT. We show here that downregulation of
Dab2 expression leads to activation of Ras/MAPK signalling, increased
production of TGFb, and the acquisition of a stable EMT phenotype.
MATERIALS AND METHODS
Cell culture, treatment and establishment of stable
cell lines
MCF10A1 cells were obtained from the Barbara Ann Karmanos
Cancer Center (Detroit, MI, USA) and cultured in DMEM/F12 media
(Mediatech, Manassas, VA, USA) containing 5% equine serum
(Invitrogen, Carlsbad, CA, USA), 20ngml
 1 EGF, 10mgml
 1
insulin, 0.5mgml
 1 hydrocortisone, 100ngml
 1 cholera toxin (all
purchased from Sigma-Aldrich, St Louis, MO, USA) and 1 
antibiotic/antimycotic solution (Gemini Bioproducts, Sacramento,
CA, USA). HME5-cdk4 cells (Ramirez et al, 2003) were cultured in
Medium 171 (Cascade Biologics, Portland, OR, USA) supplemented
with 50mgml
 1 bovine pituitary extract (Invitrogen), 20ngml
 1
EGF, 10mgml
 1 insulin, 0.5mgml
 1 hydrocortisone and 1 
antibiotic/antimycotic solution. Recombinant human TGFb1w a s
obtained from R&D Systems (Minneapolis, MN, USA) and
reconstituted as suggested. SB431542 was purchased from Sigma
and U0126 was purchased from Calbiochem (San Diego, CA, USA).
Nucleotide sequences were chosen for stable ablation of human
Dab2 using shRNA-mediated technology beginning at nucleotides
600 and 1060 (sh599-F 50-GCAACAGGCTGAACCATTA-30; sh1059-F
50-TCGACACCTTCTTCGTTTG-30), based on Genbank accession
U53446. DNA oligos were synthesised (Invitrogen), annealed and
inserted into pSIREN-retroQ (Clontech, Mountain View, CA, USA)
according to manufacturer’s instructions. Following sequence valida-
tion (DNA Sequencing Core Facility, Indiana University), negative
control (provided by Clontech) and shDab2 constructs were
cotransfected along with pCL-10A1 (Imgenex, San Diego, CA, USA)
into 293T packaging cells. Retrovirus was harvested from the media
after 48h and used to infect parental cells in the presence of 8mgml
 1
polybrene (Sigma-Aldrich), followed by selection in media containing
1mgml
 1 puromycin (Gemini Bioproducts). Stable pools of cells
expressing the various constructs were maintained in their respective
media with puromycin.
Cell lysis, immunoprecipitation and western blot analysis
Whole cell extracts were prepared by lysis in buffer D (20mM Tris,
pH 7.5, 1%, Triton X-100, 10% glycerol, 137mM NaCl, 2mM EDTA,
25mM b-glycerophosphate, 20mM Na3VO4 and COMPLETE
EDTA-free protease inhibitor mixture; Roche Diagnostics,
Indianapolis, IN, USA), sonicated and protein concentrations were
measured using Bio-Rad Protein Assay Dye Reagent Concentrate
(Bio-Rad Technologies, Hercules, CA, USA). Equal amounts of
protein were resolved on SDS–PAGE gels, transferred to PVDF
membranes (Immobilon, Millipore, Billerica, MA, USA) and
subjected to western blot analysis. For immunoprecipitation,
lysates were pre-cleared with protein G-Sepharose (Zymed,
San Francisco, CA, USA), after which primary antibody (1mg)
was added. After 4h, protein G-Sepharose beads were added for an
additional 2h. Following five washes with modified RIPA buffer
(50mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.25% deoxycholate,
1m M EDTA), immunoprecipitated proteins were eluted with 2 
Laemmli sample buffer and subjected to SDS–PAGE and western
blot analysis. Blots were developed using enhanced chemilumines-
cence (ECL-Plus, GE Healthcare, Pittsburgh PA, USA) and
visualised by autoradiography. The following antibodies were
used for western blot analysis and immunoprecipitation: Dab-2/
p96 (610465) and N-cadherin (610921) from BD Transduction
Laboratories (San Jose, CA, USA); p-ERK (sc-7383), ERK2 (sc-154),
Grb2 (sc-255), HSP90 a (sc-7947), Sos (sc-17793) and Vimentin
(sc-5565) from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Quantitative RT–PCR analysis and Origene PCR array
(Origene; Rockville, MD, USA)
Total RNA was purified using the Qiagen RNeasy Mini Prep Kit
according to manufacturer’s instructions. Using 1.0–2.5mg of total
RNA, cDNA was synthesised with SuperScript II RT (Invitrogen),
diluted and qPCR was performed for the indicated genes in
triplicate using gene specific primers and SYBR Green detection
(Roche Diagnostics) on an Applied Biosystems 7900 HT Fast
System using the following cycling parameters: 951C for 10min,
Actin
p96
p67
123456 789 1 0 1 1 1 2
Normal breast
Breast cancer
IDC IDC IDC IDC IT DCIS A IDC IDC IDC IDC IDC
Actin
p96
p67
123 4 5 6 78 9 1 0 1 1 1 2
Figure 1 Human breast tumours exhibit decreased expression of the
p96 and p67 forms of Dab2. Amplified cDNA prepared from 12 normal
and 12 breast tumour samples arrayed in a multi-well PCR plate was
obtained from the manufacturer (Origene). PCR analysis was carried out
with primers flanking the splice site for generation of the p67 isoform of
Dab2 and primers for human actin as control. Products were resolved on a
1% agarose gel and visualised by ethidium bromide staining. Amplification of
the p96 isoform results in a product of 822bp, whereas amplification of the
p67 isoform yields a product of 167bp. Images were obtained using the
Kodak 1D programme following ultraviolet illumination. Histopathological
data for individual BC samples is detailed in Supplementary Data.
Abbreviations: A¼adenoid cystic; DCIS¼ductal carcinoma in-situ,
IDC¼invasive ductal carcinoma; IT¼invasive mixed tubular.
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sfollowed by 40 cycles of 951C for 15s and 601C for 1min. After
normalisation to b-actin, relative mRNA levels were quantitated
by the DDCt method. Transcript quantitation levels are expressed
relative to that observed in untreated cells, which was set to 1.0.
Shown is the mean±s.d. from an individual experiment; indivi-
dual experiments were conducted a minimum of three times.
Primer sequences used for qPCR analysis are provided in
Supplementary Data (Supplementary Table 2).
Determination of p96 and p67 isoform expression levels in
normal and breast tumour samples was performed utilising the
Human Breast Cancer Rapid-Scan Panel (Origene) according to
manufacturer’s suggestions and performed in duplicate using the
two individual plates provided. Disabled-2 PCR was performed on
cDNA samples arrayed at 1000  concentration, whereas actin
PCR was performed on samples arrayed at 1  concentration
using primers provided by the manufacturer. Primers for Dab2
isoform discrimination were as follows: forward 50-GGGAGTGA
GGCCCTAATGATT-30 and reverse 50-GTTCTGAGACGGGAGGAG
CAAAG-30. Reactions were analyzed by gel electrophoresis in 1%
agarose gels containing ethidium bromide and visualised by UV
transillumination. Images were captured using the Kodak EDAS
290 Electrophoresis Documentation and Analysis System (Kodak;
Rochester, NY, USA).
RESULTS
Disabled-2 isoform expression is decreased in human
breast cancer
Disabled-2 is expressed as two major cellular isoforms, the full-
length p96 and the p67 isoforms, which are generated from the
same transcript by alternative splicing (Xu et al, 1995). Decreased
Dab2 protein expression has been shown in human breast tumours
by immunohistochemistry; however, the antibody utilised does
not discriminate between the two isoforms (Bagadi et al, 2006). To
further extend these observations, we probed the relative mRNA
abundance of the p96 and p67 isoforms of Dab2 in 12 normal
human breast tissue and 12 breast cancer samples using the
Human Breast Cancer Rapid-Scan Panel (Origene). By utilising
PCR primers, which flank the splice site in p67, the relative
abundance of the two isoforms can be determined based on
differing sizes of the amplified products. As shown in Figure 1,
normal breast tissue, obtained from patients undergoing reduction
mammoplasty, expresses predominantly the p96 isoform; in
addition, expression of the p67 isoform can be detected in the
majority of samples. In contrast, samples derived from breast
tumours demonstrate a marked reduction in expression of the
p96 isoform, whereas the p67 isoform is virtually undetectable
(Figure 1). Of note is the presence, but decreased expression of
detectable p96 and p67 isoforms in the ductal carcinoma in situ
(DCIS) sample (No. 11). The presence or absence of Dab2 mRNA
expression does not appear to correlate with levels of expression
of either the oestrogen or progesterone receptors as determined
by the manufacturer (Supplementary Table 1). Although we cannot
ascertain that the normal mammary tissue utilised in this study
contains equal amounts of epithelial cells, the data presented here
suggest that downregulation of both the p96 and p67 isoforms of
Dab2 occurs frequently during breast cancer progression.
Downregulation of Dab2 leads to appearance of a stable
EMT phenotype
To examine the role of Dab2 as a tumour suppressor in breast
cancer, we chose to stably downregulate Dab2 expression utilising
shRNA-mediated technology in the normal human mammary
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Figure 2 Downregulation of Dab2 leads to constitutive EMT. (A) Cell lysates were prepared from untreated or cells treated with 2.5ngml
 1 TGFb for
48h followed by western blot analysis for Dab2 expression as described in Materials and Methods. Equal protein loading is demonstrated by western blot
analysis for HSP90. Arrows indicate the position of the p96 and p67 Dab2 isoforms; Asterisk indicates a non-specific band. (B, D) Detection of Dab2 or
E-cadherin by qRT–PCR analysis in untreated and cells treated with 2.5ngml
 1 TGFb for 48h was performed as described in Materials and Methods.
Quantitation is expressed relative to levels in untreated M1 Neg cells, which is set to 1.0. Shown is the mean expression value ±s.d. from an individual
experiment; n¼3 independent experiments. (C) Upregulation of EMT marker proteins following knockdown of Dab2. Cell lysates from unstimulated or
cells treated with 2.5ngml
 1 TGFb for 48h were subjected to western blot analysis for N-cadherin (Ncad) and vimentin expression as described in
Materials and Methods. HSP90 expression by western blot analysis demonstrates equal protein loading (n¼3 independent experiments).
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sepithelial cell line MCF10A1, which harbours a defective
p16/INK4a locus (Tang et al, 2003, 2007) allowing for continued
cell growth. To determine the effectiveness of the stable knock-
down, we examined both basal and TGFb-stimulated levels of
Dab2, as TGFb has previously been shown to upregulate Dab2
expression (Jechlinger et al, 2003). Western blot analysis of lysates
from cells expressing the control virus, designated M1 Neg, show
upregulation of the p96 isoform following 48h treatment with TGFb
(Figure 2A). In contrast, M1 cells expressing the sh-599 and sh-1059
targeted constructs show reduced basal as well as TGFb-stimulated
induction of the p96 Dab2 isoform (Figure 2A). The p67 isoform
expression is shown to be reduced following TGFb treatment in all
cell lines, whereas basal levels are unaffected by the shRNA targeting
constructs. To confirm that Dab2 is downregulated at the mRNA
level, we performed qRT–PCR analysis on the various cell lines. As
shown in Figure 2B, TGFb treatment of M1 Neg cells leads to two-fold
upregulation of Dab2 message; in contrast, reduced basal and
TGFb-stimulated Dab2 levels are observed in cell lines expressing the
sh-599 and sh-1059 constructs.
During establishment of stable Dab2 knockdown pools, we did
not observe significant effects of Dab2 ablation on cell prolifera-
tion; however, we did observe differences in cellular morpho-
logy between these cells and cells expressing only the negative
control virus (Supplementary Figures 1 and 2). Untreated M1 Neg
cells exhibit a cuboidal morphology, characteristic of a normal
epithelial phenotype; however, following treatment with TGFb, the
cells acquire a fibroblastic appearance, characteristic of cells,
which have undergone EMT (Supplementary Figure 1). In contrast,
untreated M1 599 and M1 1059 cells already exhibit a mesen-
chymal morphology, which can be further accentuated on treat-
ment with TGFb (Supplementary Figure 1). During EMT, while
expression of E-cadherin is lost, expression of N-cadherin and
vimentin is gained. To confirm that the observed morphological
changes are consistent with EMT, we examined the expression of
N-cadherin and vimentin by western blot analysis and E-cadherin
mRNA expression by qRT–PCR analysis. Although TGFb treat-
ment of M1 Neg cells causes increased expression of N-cadherin
and vimentin, large increases in basal as well as TGFb-stimulated
expression of both proteins are observed in cells expressing
both the sh-599 and sh-1059 constructs (Figure 2C). In addition,
increased mRNA expression of N-cadherin and vimentin is
observed in Dab2 knockdown cells in comparison to parental
M1 Neg cells, which is maintained under both sparse and confluent
cell culture conditions (Supplementary Figure 3). At the mRNA
level, M1 Neg cells treated with TGFb exhibit a 50% reduction in
E-cadherin mRNA levels, whereas basal mRNA levels for
E-cadherin are reduced in M1 599 and M1 1059 cells by B70%
(Figure 2D). Decreased expression and relocalisation of E-cadherin
to the cytosol was also observed in M1 Neg cells treated with TGFb,
although untreated M1 599 and M1 1059 cells exhibited these same
changes as determined by immunoflourescence microscopy
(Supplementary Figure 1).
Loss of Dab2 expression leads to activation of the
Ras/MAPK signalling pathway and establishment of
an autocrine TGFb signalling loop
Previous studies have demonstrated that Dab2 overexpression can
suppress activation of the MAPK pathway (Zhou and Hsieh, 2001).
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Figure 3 Activation of Ras/MAPK signalling in Dab2 knockdown cells
leads to establishment of an autocrine TGFb signalling loop. (A) M1 Neg,
M1 599 and M1 1059 cells were unstimulated or stimulated with TGFb
(2.5ngml
 1) for 48h and subjected to western blot analysis for phospho-
ERK1/2 (pERK1/2) and total ERK2 expression as described in Materials and
Methods. (B) Equal amounts of cell lysates from TGFb-treated or
untreated cells were immunoprecipitated with a-Sos antibodies followed
by western blot analysis for Grb2 as described in Materials and Methods.
Cell lysate from untreated M1 Neg cells was run as a control (CTL) for
Grb2 visualisation. Asterisk denotes activated RAS (C, D) TGFb1, TGFb2
and TGFb3 mRNA levels were determined by qRT–PCR analysis in
untreated (C) cells, whereas PAI-1 mRNA (D) was determined
in untreated cells and in cells treated with 2.5ngml
 1 TGFb as described
in Materials and Methods. Expression is shown relative to levels in
untreated M1 Neg cells, which is set to 1.0. Shown is the mean expression
value ±s.d. from an individual experiment; n¼3 independent experiments.
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sAs Ras/MAPK signalling has been shown to cooperate with TGFb
signalling to elicit EMT (Janda et al, 2002), we next investigated
whether MAPK signalling in mammary epithelial cells is altered by
suppression of Dab2 expression. Activation of Ras initiates a
signalling cascade involving activation of Raf, which leads to the
phosphorylation and activation of MEK1/2, and subsequent
phosphorylation and activation of ERK1/2. As determined by
western blot analysis, we observed markedly increased levels of
phosphorylated ERK1 and ERK2 (p-ERK1/2) in M1 599 and M1
1059 cells, as compared with levels in M1 Neg cells (Figure 3A).
The C-terminal proline-rich domain of Dab2 has been shown to
bind to the adaptor molecule Grb2 and prevent its association with
Sos, thereby decreasing activation of the Ras signaling cascade (Xu
et al, 1998; Zhou and Hsieh, 2001). We next assessed whether loss
of Dab2 expression drives activation of the Ras pathway leading to
increased p-ERK1/2 by causing increased association of Grb2
with Sos. To determine this, cell lysates from M1 Neg, M1 599 and
M1 1059 cells stimulated with TGFb for 48h were subjected to
immunoprecipitation with a-Sos antibody followed by western blot
analysis for Grb2. As seen in Figure 3B, although TGFb treat-
ment leads to increased Grb2/Sos association in M1 Neg cells, the
level of Grb2/Sos association is significantly enhanced in the Dab2
knockdown cell lines. In addition, we observed the appearance
of slower migrating forms of Grb2 in the TGFb-treated M1 Neg
and basal as well as TGFb-treated immunoprecipitates from M1
599 and M1 1059 cells, which has been attributed to tyrosine
phosphorylation of Grb2 (Li et al, 2001).
Activation of MAPK activity has been postulated to synergise with
TGFb in induction of EMT (Janda et al, 2002), whereas maintenance
of EMT through establishment of an autocrine TGFb signalling loop
has been shown to require high levels of MAPK activity (Lehmann
et al, 2000). As many of the changes in morphological appearance
and gene expression patterns in Dab2 knockdown cells recapitulate
those observed following treatment of control cells with TGFb,w e
examined whether these cells exhibit increased mRNA expression of
the three mammalian TGFb isoforms, TGFb1, TGFb2 and TGFb3.
As shown in Figure 3C, although TGFb1 and TGFb3 levels are
modestly elevated in M1 599 and M1 1059 cells in comparison to M1
Neg cells, TGFb2 levels are increased three- to four-fold in Dab2
knockdown cells. To assess whether the increased mRNA levels of
the TGFb isoforms leads to increased production of active TGFb and
enhanced TGFb signalling, we examined the mRNA expression of
PAI-1,ac l a s s i c a lT G F b-stimulated gene (Piek et al,2 0 0 1 ) .A ss e e ni n
Figure 3D, stimulation of M1 Neg cells with TGFb leads to
upregulation of PAI-1; however, in M1 599 and M1 1059 cells basal
expression levels of PAI-1 are significantly elevated, which can be
further augmented by exogenous TGFb treatment. These results
thus suggest that the increased MAPK signalling exhibited in Dab2
knockdown cells leads to establishment of an autocrine TGFb
signalling loop.
Blockade of Ras/MAPK or TGFb signalling partially reverts
the constitutive EMT phenotype of Dab2 knockdown cells
As we have observed both upregulation of Ras/MAPK signalling
and increased expression of TGFb isoforms in Dab2 knockdown
cells, we next asked whether blockade of either pathway using
pharmacological inhibitors reverts the constitutive EMT pheno-
type observed. To assess this, M1 Neg, M1 599 and M1 1059 cells
were treated with a specific TbRI receptor kinase inhibitor
(SB431542) or a MEK1 inhibitor (U0126), in the presence or
absence of exogenous TGFb for 48h. Treatment of M1 Neg cells
with SB431542 led to loss of TGFb-stimulated induction of
N-cadherin mRNA and protein expression, whereas treatment
with U0126 led to a significant decrease in TGFb-mediated
induction of protein expression only (Figure 4A and B). Similarly,
M1 599 and M1 1059 cells treated with SB431542 failed to induce
N-cadherin mRNA and protein following TGFb treatment;
however, SB431542 treatment also led to a significant reduction
in basal mRNA levels for N-cadherin. In contrast, although U0126
treatment decreased basal N-cadherin levels in M1 599 cells only,
TGFb-stimulated induction of mRNA and protein expression
remained comparable (Figure 4A and B). To determine whether
the decreased basal expression of N-cadherin observed after
treatment with SB431542 and U0126 correlates with a blockade
of autocrine TGFb signalling, we examined the mRNA expression
of the TGFb2 isoform, which exhibits the largest increase in
expression. We find that both SB431542 and to a lesser extent
U0126 treatment leads to a significant decrease in basal expression
of TGFb2 in M1 Neg, M1 599 and M1 1059 cells.
Downregulation of Dab2 in HME-cdk4 cells facilitates
TGFb-mediated EMT
To extend these studies to another nontumourigenic mammary
epithelial cell line, we performed similar experiments in the
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Figure 4 Inhibition of TGFb or MAPK signalling abrogates TGFb-mediated EMT. (A) M1 Neg, M1 599 and M1 1059 cells were either untreated or pre-
treated for 30min with 10mM SB431542 (SB) or 10mM U0126 (UO) followed by addition of TGFb (2.5ngml
 1) for 48h. Cell lysates were prepared and
western blot analysis performed to determine N-cadherin (Ncad) expression levels as described in Materials and Methods (n¼2 independent experiments).
(B, C) qRT–PCR analysis was performed to determine relative expression levels of N-cadherin, TGFb1, TGFb2 and TGFb3 mRNA following the
treatments described in A. Shown is the mean±s.d. of triplicate assays with M1 Neg unstimulated levels set to 1.0 (n¼2 independent experiments).
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breast augmentation, which possesses an extended in vitro culture
lifespan due to overexpression of cdk4 (Ramirez et al, 2003). As
shown in Figure 5, stable knockdown of Dab2 in HME-cdk4 cells
(Figure 5A) leads to a constitutive EMT phenotype, characterised
by increased protein expression of N-cadherin and vimentin
(Figure 5B). In addition, similar to results obtained in M1 599 and
M1 1059 cells, elevated Ras/MAPK signalling and increased
expression of TGFb2 and TGFb3 is observed in the Dab2
knockdown cell lines (Figure 5C and D).
DISCUSSION
Loss of Dab2 expression is associated with breast cancer
progression and EMT
The process of epithelial-to-mesenchymal transition, although
critical for proper embryonic development, has recently been
linked with aggressive, invasive and metastatic behaviour of
various cancer types, including breast cancer (Yang and Weinberg,
2008; Tan et al, 2009). Transforming growth factor b signalling
exerts potent growth–inhibitory effects in normal epithelial cells;
however, late in tumour progression, TGFb has been shown to
cooperate with other pro-oncogenic pathways to support tumour
progression, which may be due to the ability of TGFb to stimulate
EMT (Xu et al, 2009). Indeed, increased levels of TGFb have been
observed in human breast cancer samples, which are associated
with expression of a pro-invasive, angiogenic and metastatic gene
expression profile (Sarrio et al, 2008). Here, we demonstrate that
decreased expression of the tumour suppressor Dab2 leads to
activation of Ras/MAPK signalling, which initiates the establish-
ment of an autocrine TGFb signalling loop and stable EMT
(Figure 6).
Although decreased Dab2 mRNA levels were observed in all
human breast cancer samples analyzed, irrespective of tumour
grade, the decreased expression of Dab2 in the DCIS sample
suggests that Dab2 loss occurs early in breast cancer progression
(Figure 1 and Supplementary Table 1). Our results are thus
consistent with a previous study, which determined that Dab2
protein levels were decreased in 74% of breast tumour samples
examined (Bagadi et al, 2006). To study the role of Dab2 in breast
cancer progression, we have utilised two normal mammary
epithelial cell lines MCF10A1 and HME5-cdk4. Although the
MCF10A1 cell line contains an inactivated p16 locus (Tang et al,
2007), overexpression of cdk4 in HME5 cells allows them to
overcome p16-mediated growth arrest and continue to grow in
culture (Ramirez et al, 2003). Breast tissue obtained from normal
healthy women was found to contain variant HMECs (vHMECs),
which exhibited p16 promoter hypermethylation both in vitro and
in vivo (Crawford et al, 2004). When cultured in vitro, these
vHMECs went on to acquire chromosomal abnormalities seen in
premalignant lesions of breast cancer and further progressed to
display invasive behaviour, suggesting that p16 inactivation
identifies a sub-population of mammary epithelial cells, which
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Figure 5 Downregulation of Dab2 in HME5-cdk4 (K4) cells results in a
constitutive EMT phenotype. (A, B) Cell lysates from unstimulated cells or
cells treated with 2.5ngml
 1 TGFb for 48h were subjected to western
blot analysis for Dab2, N-cadherin (Ncad) and vimentin expression as
described in Materials and Methods. HSP90 expression by western blot
analysis demonstrates equal protein loading (n¼3 independent experi-
ments). Arrow indicates the position of the p96 Dab2 isoform; Asterisk
indicates a non-specific band. (C) K4 Neg, K4 599 and K4 1059 cells were
untreated or stimulated with TGFb (2.5ngml
 1) for 48h and subjected to
western blot analysis for phospho-ERK1/2 (pERK1/2) and total ERK2
expression as described in Materials and Methods. (D) Elevated expression
levels of TGFb isoforms exhibited by Dab2 knockdown cells. Transforming
growth factor b1, TGFb2 and TGFb3 mRNA expression was determined
by qRT–PCR analysis in untreated K4 Neg and shDab2-expressing cells as
described in Materials and Methods. Shown is mean±s.d. from assays
performed in triplicate with expression in K4 Neg set to 1.0. (n¼3
independent experiments).
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et al, 2004). MCF10A1 and HME5-cdk4 cells thus provide a
relevant model system to study the effects of Dab2 downregulation
early in breast cancer development.
In our study, we have downregulated Dab2 expression utilising
shRNA-mediated technology; however, the mechanism whereby
Dab2 expression is decreased in the course of breast cancer
development remains undetermined. A recent study detected Dab2
promoter hypermethylation in 11% (6 out of 54) of primary breast
tumours, whereas overall 74% (67 out of 91) of breast tumours
analyzed displayed decreased Dab2 protein expression, leading
the authors to suggest that Dab2 promoter hypermethylation is an
infrequent cause for loss of Dab2 expression in breast cancer
(Bagadi et al, 2006). Although not determined in this study, it is
tempting to speculate that Dab2 promoter hypermethylation is
associated with a specific subtype of breast cancer, the basal
subtype, as these tumours have been shown to specifically exhibit
an EMT-like phenotype (Dumont et al, 2008; Sarrio et al, 2008).
Indeed, MDA-MB 231 cells, a metastatic basal-like breast cancer
cell line, which expresses EMT markers, exhibits Dab2 promoter
hypermethylation (Bagadi et al, 2006).
Regulation of Ras/MAPK signalling by Dab2
TGFb treatment has long been known to lead to activation of
MAPK signalling; however, until recently the mechanism by
which activation of the TGFb receptors led to activation of Ras
remained unclear. Lee et al (2007) reported that activated TbRI
binds and phosphorylates ShcA proteins on tyrosine and serine
residues, which induces the recruitment of Grb2 and Sos to
TbRI, and hence activation of Ras, Raf and ERK. Here, we show
that TGFb stimulation leads to increased Grb2/Sos association
(Figure 3). As it has already been suggested that a competition
exists between Dab2 and Sos for the binding of Grb2 (Xu et al,
1998), decreased expression of Dab2 may enhance TGFb-
stimulated Ras/ERK signalling by shifting the levels of Grb2
available for binding to ShcA. Alternatively, the p96 isoform
of Dab2, through its role as an endocytic adaptor molecule
(Morris and Cooper, 2001), may direct the TGFb receptors to
clathrin-coated pits. Athough the TGFb receptors have been shown
to reside in both clathrin-coated pits and lipid raft compart-
ments of the cell membrane (Di Guglielmo et al, 2003), receptor
localisation in lipid raft structures was shown to be required
for TGFb-stimulated MAPK activation and EMT, but not
TGFb-mediated phosphorylation of Smad2/3 (Zuo and Chen,
2009). Loss of Dab2 expression may thus shift localisation of TGFb
receptors to lipid raft compartments leading to increased MAPK
signalling and EMT.
Cooperation between the Ras/MAPK and TGFb signalling
pathways has been postulated to be important for induction and
maintenance of stable EMT. In mouse EpH4 cells, expression of
oncogenic Ha-ras was required for the cells to undergo EMT in the
presence of TGFb (Janda et al, 2002), whereas in human vHMECs,
expression of Ha-ras in the presence of 10% serum or TGFb was
shown to trigger sustained induction of EMT leading to repression
of E-cadherin (Dumont et al, 2008). Although activation of the Ras
pathway is commonly observed in breast cancer, this is not due to
oncogenic activation of the Ras proteins (Clark and Der, 1995). We
show here that stable downregulation of Dab2 leads to potent
stimulation of the Ras/MAPK pathway (Figures 3 and 5), resulting
in enhanced expression of TGFb and establishment of an autocrine
TGFb signalling loop, which is consistent with the finding that
blockade of MAPK signalling or blockade of TGFb signalling
decreases the EMT phenotype in Dab2 knockdown cells. Loss of
Dab2 expression may thus supply activation of the Ras pathway in
breast cancer, which along with other genetic changes, leads to the
development of the aggressive and basal subtype of breast cancer.
Autocrine TGFb2 signalling and tumour progression
Although treatment of cells with all three isoforms of TGFb has
been shown to induce EMT in culture, individual isoforms
have been shown to have distinct roles in regulation of EMT in
developmental processes. During heart development, it was found
that TGFb2, but not TGFb1 or TGFb3, mediated cardiac cushion
EMT, which is important for cardiac valve formation (Azhar et al,
2009). Transforming growth factor b3, on the other hand, is
required for induction of EMT in medial-edge epithelial cells,
important for palate cleft fusion (Nawshad et al, 2007). In breast
cancer, overexpression of TGFb1 was found to be associated with
a higher occurrence of distant metastasis (Tan et al, 2009). We find
that decreased expression of Dab2 in two normal mammary
epithelial cell lines leads to upregulation of the TGFb2 isoform,
whereas expression of TGFb1 and TGFb3 isoforms are also
stimulated to a lesser extent (Figures 3 and 5). In breast cancer,
presence of a novel 4bp insertion in the TGFb2 promoter, which
leads to increased promoter activity, was shown to be associated
with lymph node metastasis (Beisner et al, 2006), suggesting that
the TGFb2 isoform may contribute to breast cancer metastasis
through induction of EMT in mammary epithelial cells.
In conclusion, we show here that downregulation of Dab2, which is
commonly observed in breast cancer, can lead to enhanced
Ras/MAPK signalling, increased expression of TGFb2 and constitutive
EMT (Figure 6). Breast cancer metastasis has been correlated with
the appearance of an EMT-like phenotype, which is postulated to be
controlled by MAPK and TGFb signalling. As global targeting of TGFb
signalling may not be desirable because of its function as a tumour
suppressor in normal epithelial cells, strategies targeting TGFb2
isoform expression may provide the specificity required to block only
the pro-metastatic functions of the TGFb signalling pathway. A further
understanding of pathways modulated by Dab2, as well as the control
of Dab2 expression itself, may thus provide additional targets for
intervention in the metastatic process.
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Figure 6 Loss of Dab2 facilitates EMT. In the basal state, cytosolic Grb2
can be found in association with Dab2 or Sos. Loss of Dab2 expression,
commonly observed in breast cancer, is postulated to increase the
proportion of Grb2 associated with Sos, resulting in Ras activation (RAS*),
stimulation of MAPK signalling and phosphorylation of ERK (pERK).
Activation of ERK stimulates increased transcription of the TGFb isoforms,
in particular the TGFb2 isoform. Increased TGFb stimulation induces
transient EMT, and also initiates establishment of an autocrine TGFb
signalling loop leading to a stable EMT phenotype exemplified by increased
expression of EMT markers. Inhibition of TGFb signalling with SB431542 or
MAPK signalling with U0126 decreases TGFb production and causes partial
reversion of the EMT phenotype.
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